Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462577 | 0.92 | MME (0.38) | MMEPLK1 | |
| SCHEMBL12788594 | 0.92 | MME (0.41) | MMEPLK1 | |
| SCHEMBL13274125 | 0.83 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL25590716 | 0.82 | EPHX1 (0.35) | — | |
| SCHEMBL22046874 | 0.81 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL25590423 | 0.80 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL25587321 | 0.79 | — | — | |
| SCHEMBL22169754 | 0.78 | — | — | |
| SCHEMBL1222687 | 0.77 | — | — | |
| SCHEMBL20043193 | 0.76 | MAOB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | BEIGENE, LTD. (KY) | 2022-01-11 | — | — | US | disclosed |
| US-20200207774-A1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2020-07-02 | — | — | US | disclosed |
| WO-2019047915-A1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE, LTD. (KY) | 2019-03-14 | — | — | WO | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207774-A1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS | PIK3CD, PIK3R5, PIK3CA | MME 4878/4885L3MBTL1 3962/4885PLK1 658/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MME 3819/4885L3MBTL1 3355/4885PLK1 3078/4885 |
| US-11220506-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors | PIK3CD, PIK3R5, PIK3CA | MME 4878/4885L3MBTL1 3962/4885PLK1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.